Tsubota Laboratory Incorporated [4890.T]
TOKYO, May 14 (Pulse News Wire) – Tsubota Laboratory Incorporated (4890.T) reported a significant revenue decline and lower net profit for the fiscal year ending March 2026. Sales was ¥200 million, down 85.3% from the previous year's figure of ¥1.373 billion.
Operating profit also dropped sharply to negative ¥787 million compared to positive ¥235 million last year. Despite the downturn, the company maintained its research and development investment at ¥277 million, up slightly from ¥254 million in the prior year. Management attributed the shortfall primarily to delays in large contract closures, leading to missed revenue targets. However, operational expenses were reduced by 2.3%, demonstrating efforts to control costs amid challenging conditions.
Looking ahead, Tsubota Laboratory plans to continue advancing its pipeline projects, including Phase 2a trials for TLM-001, a treatment for meibomian gland dysfunction, and Phase 2 trials for TLM-003, a drug to inhibit myopia progression. Additionally, the company expects to expand its cosmetics division and pursue opportunities in light therapy technology to ensure stable revenue streams. For the fiscal year ending March 2027, Tsubota Laboratory forecasts sales growth to reach between ¥1.1 billion and ¥1.2 billion, aiming for a return to profitability with operating income projected between ¥792 million and ¥837 million. Research and development spending is set to increase to approximately ¥400 million to support ongoing innovation and product development.
🟢 Confidence: High AI-translated content.